OrthoPediatrics (NASDAQ:KIDS) Director Sells $403,262.00 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 16,300 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $24.74, for a total transaction of $403,262.00. Following the completion of the sale, the director owned 6,881,464 shares of the company’s stock, valued at $170,247,419.36. The trade was a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS opened at $23.65 on Friday. The firm’s 50-day moving average price is $21.41 and its 200-day moving average price is $18.66. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74. The firm has a market capitalization of $617.50 million, a P/E ratio of -14.08 and a beta of 0.98. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The company had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. Equities research analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on KIDS. BTIG Research boosted their price objective on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Needham & Company LLC lifted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Finally, Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, OrthoPediatrics presently has an average rating of “Moderate Buy” and a consensus target price of $26.44.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC boosted its position in shares of OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after buying an additional 452,840 shares during the last quarter. BlackRock Inc. purchased a new stake in OrthoPediatrics in the 2nd quarter valued at $24,347,000. Vanguard Group Inc. raised its position in OrthoPediatrics by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after buying an additional 10,927 shares during the last quarter. Granahan Investment Management LLC lifted its stake in OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after acquiring an additional 232,760 shares in the last quarter. Finally, Wasatch Advisors LP lifted its stake in OrthoPediatrics by 56.6% during the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after acquiring an additional 186,357 shares in the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.